Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A
Launched by WYETH IS NOW A WHOLLY OWNED SUBSIDIARY OF PFIZER · Aug 30, 2005
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male subjects with severe or moderately severe hemophilia A
- • A negative past medical history of a Factor VIII inhibitor
- • Age greater than or equal to 12 years
- Exclusion Criteria:
- • A history of Factor VIII inhibitors
- • Presence of a bleeding disorder in addition to hemophilia
- • Known hypersensitivity to hamster protein
About Wyeth Is Now A Wholly Owned Subsidiary Of Pfizer
Wyeth, now a wholly owned subsidiary of Pfizer, is a global biopharmaceutical company dedicated to advancing healthcare through innovative research and development. With a strong legacy in the pharmaceutical industry, Wyeth focuses on discovering and delivering medicines that address significant medical needs across various therapeutic areas, including vaccines, biologics, and specialty pharmaceuticals. Leveraging Pfizer's extensive resources and expertise, Wyeth continues to drive scientific advancement and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Perth, , Australia
Madrid, , Spain
Valencia, , Spain
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Groningen, , Netherlands
Wroclaw, , Poland
New Orleans, Louisiana, United States
Buffalo, New York, United States
Poznan, , Poland
Auckland, , New Zealand
Atlanta, Georgia, United States
Dayton, Ohio, United States
Houston, Texas, United States
Leuven, , Belgium
Milano, , Italy
Salt Lake City, Utah, United States
Iowa City, Iowa, United States
Berlin, , Germany
Stockholm, , Sweden
San Diego, California, United States
Nashville, Tennessee, United States
Sacramento, California, United States
New Hyde Park, New York, United States
Helsinki, , Finland
Rouen, , France
Aurora, Colorado, United States
Charlottesville, Virginia, United States
Chapel Hill, North Carolina, United States
New Brunswick, New Jersey, United States
Worcester, Massachusetts, United States
Phoenix, Arizona, United States
Hamilton, , New Zealand
Budapest, , Hungary
East Lansing, Michigan, United States
St. Louis, Missouri, United States
Le Kremlin Bicêtre, , France
Muenster, , Germany
Lodz, , Poland
Warszawa, , Poland
Malmö, , Sweden
Patients applied
Trial Officials
Medical Monitor
Study Director
Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
Principal Investigator
For Germany, MedInfoDEU@wyeth.com
Trial Manager
Principal Investigator
For Italy, descresg@wyeth.com
Trial Manager
Principal Investigator
For Australia, New Zealand, medinfo@wyeth.com
Trial Manager
Principal Investigator
For Netherlands, trials-NL@wyeth.com
Trial Manager
Principal Investigator
For Sweden, Finland,MedInfoNord@wyeth.com
Trial Manager
Principal Investigator
For Hungary, WPBUMED@wyeth.com
Trial Manager
Principal Investigator
For Poland, WVWZMED@wyeth.com
Trial Manager
Principal Investigator
For Belgium, trials-BEL@wyeth.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials